Introduction
Streptococcus pneumoniae (S. pneumoniae) is a major global pathogen that poses a risk of pneumococcal pneumonia and invasive pneumococcal disease (IPD) with considerable morbidity and mortality particularly among extreme age groups < 5 and ! 65, particularly in travellers, including Hajj pilgrims. [1] [2] [3] An increase in antibiotic resistance have led the researchers to divert attention to search for novel vaccines such as the pneumococcal conjugate vaccine (PCV) that would be providing broader coverage for many developing countries. 4 Despite the great benefits of the pneumococcal vaccines, there are still technical factors limiting the potential impact of immunization, particularly in some developing countries, such as the cost and the fact that many vaccines require repeated administration in order to achieve effective protection. While PCVs are widely available in industrialized nations, the cost of these vaccines is still considered a great challenge to comprehensive implementation in low-and middle-income countries as these countries are lagging behind the required schedule due to vaccine costs. [5] [6] [7] From another prospective, adult international travellers from developing and developed countries who perform Hajj pilgrimage in Saudi Arabia are required to receive multiple vaccinations such as the tetravalent meningococcal vaccine which is a mandatory visa requirement. 8 Pilgrims who are incompletely immunized are also encouraged to be up-to-date with the immunization schedule in their home country; these usually include diphtheria, tetanus, pertussis, polio, measles and mumps. 8 Additionally, independent experts and the Saudi Thoracic Society also recommend pneumococcal vaccine for Hajj pilgrims particularly for those who are highly susceptible to the infection. 3, 9 This is consistent with the Australian guidelines that recommend pneumococcal vaccine to vulnerable populations such as elderly and/or people with comorbidity. 10 The requirement of receiving multiple vaccines raises the concern about potential interactions between vaccine components reducing desired protective effects. 11, 12 Glycoconjugate vaccines are covalently bound to a carrier protein which provides T-cell epitopes that confer a T dependent character to the saccharide moiety. The three most common carrier proteins currently included in licensed glycoconjugate vaccines are diphtheria toxoid (DT), tetanus toxoids (TT) and CRM197, a non-toxic mutant of diphtheria toxin. 13 The antigenic similarity between these carrier proteins and the components of tetanus, diphtheria and acellular pertussis (Tdap) vaccine is the corner stone of potential interactions. There have been suggestions to take advantage of conjugate vaccine interactions especially to investigate if carrier priming occurs which would enhance the immunogenicity of PCV and perhaps spare one of the three (expensive) doses for children in developing countries. 14, 15 However, this interaction has not yet been examined thoroughly through an RCT in either children or adults as literature suggest that prior exposure to Tdap vaccine could unpredictably enhance or suppress the subsequent immunogenicity of the conjugate vaccine. 16 The Hajj pilgrimage provided a unique opportunity to conduct several comparisons to allow for examination of coadministration vs sequential administration of glycoconjugate vaccines with Tdap. This examination will provide further evidence on conjugate vaccine interactions, whether priming (enhancement) or interference (suppression).
In the year 2014, our team examined this by an RCT comparing concurrent vs sequential administration of Tdap with two other conjugate vaccines conjugated to CRM197 (PCV13 and MCV4). 17 This showed significant suppression to six (of the 13) antigens of PCV13 after prior exposure to Tdap; the suppression was attributed then to possible CRM197 overload. The objective of this study is to present the outcome of the next year's RCT (2015) 
Methods

Study Design
We conducted an open label randomized controlled trial from 14 February to 18 August in the year 2015 at The Children's Hospital at Westmead (CHW), Sydney, Australia, in order to determine in adults whether prior or concurrent exposure to Tdap vaccine, primes or suppresses antibody responses to PCV13 coadministered with MCV4. In this paper, we present the pneumococcal serotype specific antibody data. Meningococcal, diphtheria and tetanus antibody results were already reported previously (currently under review).
Participants
Pilgrims aged 18-64 years who were able to give informed consent were recruited from Greater Sydney, New South Wales (NSW) through Hajj travel agents. Persons excluded from participation were those who, in the past 3 years, had received any vaccine containing diphtheria, tetanus, pertussis, meningococcal or pneumococcal antigens, or who had contraindications to receipt of those vaccines as listed in the NHMRC Australian Immunisation Handbook 10th Edition. 10 
Study Groups
Each participant was randomly assigned according to computer-generated random numbers to any one of the three study groups ( Figure 1 Group C: Initially vaccinated with PCV13 (right deltoid) plus MCV4 (left deltoid) followed 3-4 weeks later by Tdap (left deltoid).
Each subject provided a 3-5 ml blood sample at each visit and 3-4 weeks after the last vaccination.
Sample Size Calculation
This trial's sample size was actually based on the impact on the immunogenicity of the MCV4, one of the study vaccines.
Studies with MCV4 among adults have shown that a minimum 4-fold response to serogroup (Y) to be as low as 74%. With power of 80% and a two-sided a ¼ 0.025, a sample size of 72 participants per group will give the power to detect a 25% relative increase from 74% to 92.5%. We would be also able to detect a reduction in response approximately from 74% to 49.5%. To account for 5% loss to follow-up, approximately 76 per group are required i.e. a total of 227 participants in the three groups. We did not do a formal sampling size calculation in relation to response to pneumococcal conjugate vaccine and we recognize that power is limited by the number of subjects recruited.
Antibody Assays
Blood samples were stored at þ2 and þ8 C until centrifuged on the same day of collection and serum was extracted, divided into aliquots and stored at À80 C until transported frozen to Pfizer's Laboratory at Pearl River, NY, USA, for opsonophagocytic activity (OPA) assays 18 for pneumococcus Serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F.
For this study, antibody titres against pneumococcal antigens were measured using OPA as it reflects the ability of antipneumococcal antibodies to induce phagocytosis and killing. 19 
Statistical Analysis
Data were compiled into a Microsoft Excel 2013 spreadsheet and then exported to Statistical Package for the Social Sciences (SPSS, Inc., Chicago, IL, USA) version 22 for analysis.
Primary comparison among the three study groups was performed by calculating geometric mean titres (GMTs) of antibodies and 95% confidence intervals, by treatment group, postvaccination for each antibody assayed. A generalized linear model, with log-transformed antibody titres, was compared for the three study groups using analysis of variance (ANOVA) test.
Secondary comparison of the three study groups involved binary logistic regression and Chi-square tests (or Fishers exact test when expected cell count < 5) to compare the proportions (frequencies) of subjects that achieved OPA titre ! 1:8 post-vaccination or where seroresponders with a ! 4-fold rise in OPA titre. When the overall p value for the model analyzing the three study groups was significant, further univariate analysis was conducted between two relevant study arms. 
Ethical Aspects and Trial Registration
Results
Of the 166 subjects enrolled, 159 (95.7%) completed the study according to protocol (Figure 1) . Six withdrew because they could not comply with the study schedule and one because of a non-serious adverse event. The 159 participants were aged 18-62 (median 42) years; 85 (53%) were males. Their countries of birth were Australia (n ¼ 37), Lebanon (28), Indonesia (24), Pakistan (18), Bangladesh (16) plus other Asian pacific (28) and Middle East countries (8) . Thirty-one of them had chronic medical conditions (11 had diabetes, 4 had asthma, 3 had hypertension, 3 had arthritis, 3 had chronic back pain and one each had allergic rhinitis, cardio vascular disease, cerebrovascular disease, diverticulitis, epilepsy, gout and hypothyroidism). Table 1 shows that there was significantly (P < 0.05) lower GMTs in Group A compared with the other groups for seven serotypes (1, 14, 18C, 3, 4, 5 and 9V). On the other hand, Group C had significantly lower GMTs for two serotypes (19F and 6A) compared with the other two groups; whereas Group B had (insignificantly) lower GMTs for only one serotype (23F). The pattern of these comparisons is illustrated in Figure 2 .
Generally, upon comparing the GMTs across the three study groups, the highest GMT among all groups and serotypes was 6A in Group B and the lowest serotype response was serotype 3 in Group A.
With regard to achieving ! 4-fold rise in OPA titre, Table 2 details by assigned group the numbers and proportions of those with ! 4-fold rise. A lower proportion of Group A subjects achieved ! 4-fold rise for Serotypes 18C (P¼ 0.06) and 5 (P¼ 0.01) compared with the other two groups. In Group B, responses were generally better.
Group C had a significantly lower proportion of subjects achieving the ! 4-fold rise for, just one, Serotype 6A.
In terms of numbers and proportions of seropositive subjects (OPA titre ! 1:8), there was no significant differences across the three groups in terms of achieving seropositive titres ! 1:8 (Table 3) .
Discussion
This trial highlights that exposure to Tdap 3-4 weeks before the coadministration of PCV13/MCV4 in adults (as in Group A) significantly suppressed the subsequent GMTs to seven (1, 14, 18C, 3, 4, 5 and 9V) of the PCV13's polysaccharide serotypes. Additionally, two of these serotypes (18C and 5) in Group A showed significantly lower proportion achieving ! 4-fold rise in OPA titres. The concurrent exposure to Tdap in Group B resulted in a better immune response and no evidence of significantly lower proportion achieving ! 4-fold rise for any serotype. It is noteworthy to mention that concurrent administration of pneumococcal conjugate vaccine with other vaccines such as and influenza vaccine may variably affect the response to pneumococcal vaccine. [20] [21] [22] Carrier proteins can induce anti-carrier antibody responses that may interfere with immune responses to the conjugate vaccine upon concurrent or especially sequential administration to Tdap. This trial indicates that Tdap antigens can negatively interact with at least half of serotypes of the CRM197-conjugated PCV13, probably as a result of the similarity of the carrier protein CRM197 to DT in Tdap. The prominent suppression in some serotypes more than others may be due to lack of power or could be attributed to the different immunological properties of the structurally different pneumococcal antigens. 23 There are very few trials in the literature examining the impact of sequential administration of Tdap and conjugate vaccines. In contrast to our finding, two pre-clinical studies in mice demonstrated that prior exposure to TT and CRM197 subsequently enhanced the immunity of TT-conjugated pneumococcal vaccine and CRM-197 conjugated PCV13, respectively. 24, 25 Furthermore, some infant and adult studies have also found evidence that prior receipt of DTP vaccine or one of its components enhanced the subsequent immunogenicity of PCV-DT/CRM197. 14,26-29 These findings can be attributed to carrier priming phenomenon which arises from the increased the number of carrier specific T lymphocytes that can provide the Figure 2 . GMTs and confidence intervals of OPA for all the PCV13 serotypes, 3-4 weeks post-vaccination with PCV13 (coadministered with MCV4) administered either before, concomitantly or after Tdap. Group A, Tdap before PCV13 and MCV4; Group B, Tdap with PCV13 and MCV4; Group C, PCV13 and MCV4 before Tdap; MCV4, quadrivalent meningococcal TT conjugate vaccine; PCV13, 13-valent pneumococcal CRM197 conjugate vaccine; Tdap, combined tetanus, reduced diphtheria and acellular pertussis vaccine; OPA, opsonophagocytic assay; GMT, geometric mean titre. Table 2 . Proportions of subjects with ! 4-fold rise in OPA titre for the 13 serotypes of PCV13, 3-4 weeks post-vaccination with PCV13 (coadministered with MCV4) administered either before, concomitantly or after Tdap necessary 'help' for the expansion and differentiation of polysaccharide specific B lymphocytes. 30, 31 On the other hand, our trial among adults in the year 2014 with similar design has shown that prior exposure to Tdap resulted in the suppression of the GMTs of six serotypes (3, 5, 18C, 4, 19A and 9V) of PCV13. 17 It was thought that the suppression was due to the overload of CRM197 which was present in the PCV13 (Prevnar TM ) and MCV4 (Menveo TM ).
However, the suppression also occurred in this 2015 trial even with a lower CRM197 dose as we replaced Menveo with TT-conjugated MCV4 (Nimenrix TM ). The suppression in 2014
and 2015 occurred nearly in the same serotype which implies that it is a serotype-specific suppression. This suppression could be attributed to immunological phenomena such as CIES 24, [32] [33] [34] [35] in which antibody responses to haptens presented on a carrier are inhibited by prior immunization with the specific carrier. 36 This occurs due to the presence of pre-existing antibodies to the carrier protein that may prevent the binding of hapten-specific B-cells to their epitopes. Additionally, the promotion of dominant carrier-specific B cells may consume local sources of immune help (T cells) resulting in depriving hapten-specific B-cells of necessary resources leading to reduced antigen induced antibodies.
37-39
It is not entirely clear why carrier priming occurred in some studies while in CIES others, but the mice models with carrier priming attributed the results to the very large amount of the pneumococcal polysaccharide compared with CRM (antigen to carrier molecular size ratio of _> 2) which means that anti-CRM antibodies would not cause steric hindrance, whereby pre-existing carrier-specific antibody prevent access of B cells to the haptens resulting in CIES. 25 An inverse dose-dependent relationship of the priming agent to the antibodies produced against the polysaccharide the conjugate vaccine was observed. 24 This highlights that the relative size of antigen and carrier influences the extent of such immune suppression by pre-existing anti-carrier antibody. Several solutions have been suggested to avoid CIES, for instance, animal models have shown that moderate conjugation of polyethylene glycol (PEGylation) of the vaccine has reduced CIE. 40 Additionally, it has been suggested that increasing hapten load, use of less prevalent carriers or providing novel carriers might help to overcome immune interference in multi-valent vaccines containing several polysaccharide-conjugate antigens. 13, 25 The three study groups in this trial have achieved a similar immune response in terms of proportion with an OPA titre ! 1:8 post-vaccination; this best reflects short term protection 41 ; whereas the GMTs of OPA which are more representative of long-term protection showed significant suppression upon prior exposure to Tdap. An important limitation is the small sample size, also we cannot completely disregard the effect of MCV4 as PCV13 was not administered solely. However, we showed from our analysis of the 2014 RCT that even a smaller sample size was associated with significant differences. 17 
